venBio Partners LLC — 13F Holdings & Portfolio
CIK 1776382 · latest 13F-HR filed 2026-05-15
venBio Partners LLC manages $280.6M in 13F-reported U.S. long-equity assets across 6 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are PHVS (46.71%), ALMS (35.56%), ALXO (9.21%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 0 new positions, exited 0, added to 3, and trimmed 2.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$280.6M
Long-equity book
6
Distinct positions
2026-03-31
Filed 2026-05-15
+0 / −0 / ↑3 / ↓2
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- ALUMIS INC$54.7M +121.3%
- ALX ONCOLOGY HLDGS INC$14.9M +135.7%
- ARTIVA BIOTHERAPEUTICS INC$639.7K +23.0%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | PHARVARIS N V | PHVS | N69605108 | $131.1M | 46.71% | 4,639,304 | SH |
| 2 | ALUMIS INC | ALMS | 022307102 | $99.8M | 35.56% | 4,528,408 | SH |
| 3 | ALX ONCOLOGY HLDGS INC | ALXO | 00166B105 | $25.8M | 9.21% | 12,884,638 | SH |
| 4 | HARMONY BIOSCIENCES HLDGS IN | HRMY | 413197104 | $13.7M | 4.88% | 489,194 | SH |
| 5 | LYELL IMMUNOPHARMA INC | LYEL | 55083R203 | $6.8M | 2.41% | 337,697 | SH |
| 6 | ARTIVA BIOTHERAPEUTICS INC | ARTV | 04317A107 | $3.4M | 1.22% | 531,337 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $280.6M | 6 | 0000905148-26-002409 |
| 2025-12-31 | 2026-02-17 | $216.3M | 6 | 0000905148-26-000841 |
| 2025-09-30 | 2025-11-14 | $176.4M | 6 | 0000905148-25-004034 |